68Ga-NY104 PET/CT in Von Hippel-Lindau Disease
Phase 2
Recruiting
- Conditions
- Von Hippel-Lindau Disease
- Interventions
- Diagnostic Test: 68Ga-NY104 PET/CT Contrast-enhanced MRI of the brain and contrast-enhanced CT of abdomen and pelvis) 68Ga-NODAGA-LM3 PET/CT (exploratory)
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT05810246
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer
Phase 2
Recruiting
- Conditions
- Optical Surface Monitoring TechnologyBreast CancerLarge-segment Radiotherapy
- Interventions
- Device: Surface Guided Radiation Therapy (SGRT)
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 556
- Registration Number
- NCT05804916
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT05803915
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Characterizing Histiocytosis With 68Ga-FAPI PET/CT
Not Applicable
Not yet recruiting
- Conditions
- Histiocytosis
- Interventions
- Diagnostic Test: 68Ga-FAPIDiagnostic Test: 18F-FDG
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05803629
- Locations
- 🇨🇳
Department of Nuclear Medicine, Peking Union Medical College Hopital, Chinese Academy of Medical Science, Beijing, China
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
Not Applicable
Recruiting
- Conditions
- Locally AdvancedPancreatic Cancer
- Interventions
- Drug: Later-line therapy
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05802394
- Locations
- 🇨🇳
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
Not Applicable
Recruiting
- Conditions
- Pancreatic CancerAdvanced CancerMetastatic Cancer
- Interventions
- Drug: Later-line therapy
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05802420
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
the Safety and Effectiveness of Protein Supplements on Cancer Patients With Nutritional Risk and Malnutrition
Not Applicable
Not yet recruiting
- Conditions
- MalnutritionCancer
- Interventions
- Dietary Supplement: protein supplementBehavioral: nutrition counseling
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05802381
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
Not Applicable
Recruiting
- Conditions
- Resectable CarcinomaPancreatic Cancer
- Interventions
- Drug: Later-line therapy
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05802407
- Locations
- 🇨🇳
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement
Not Applicable
Recruiting
- Conditions
- Autoimmune Diseases
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05789017
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
Not Applicable
Recruiting
- Conditions
- Autoimmune Diseases
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05789030
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath